NEW YORK (GenomeWeb) – Macrogen and Silicon Biosystems Menarini announced today that they are partnering to co-develop CLIA-certified genomic tests for different cancers.

The companies plan to combine Silicon Biosystems' DEPArray digital-sorting technology with Macrogen's high-throughput whole-genome, whole-exome, and targeted sequencing systems to resolve cellular heterogeneity of formalin-fixed paraffin-embedded (FFPE) biopsies and fine-needle aspiration (FNA) samples.

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.